Disease · MONDO_0005061
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Afatinib 50 mg/Day vs Placebo: serious adverse events | 136 of 390 | 36 of 195 | 585 | NCT00656136 | Trial comparisons |
| Afatinib 40 Milligram (mg) vs Gemcitabine / Cisplatin Chemotherapy: deaths from any cause | 16 of 239 | 3 of 113 | 352 | NCT01121393 | Trial comparisons |
| Afatinib 40 Milligram (mg) vs Gemcitabine / Cisplatin Chemotherapy: serious adverse events | 40 of 239 | 12 of 113 | 352 | NCT01121393 | Trial comparisons |
| Afatinib 40 mg vs Pemetrexed/Cisplatin Chemotherapy: serious adverse events | 72 of 229 | 25 of 111 | 340 | NCT00949650 | Trial comparisons |
| Afatinib vs Gefitinib: deaths from any cause | 126 of 160 | 132 of 159 | 319 | NCT01466660 | Trial comparisons |
| Afatinib vs Gefitinib: serious adverse events | 75 of 160 | 64 of 159 | 319 | NCT01466660 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 14 of 109 | 5 of 110 | 219 | NCT01404260 | Trial comparisons |
| Arm A: Erlotinib vs Arm B: Erlotinib/Carboplatin/Paclitaxel: Number of Participants With Grade 3, 4 or 5 Adverse Event at Least Possibly Related to Treatment. | 20 of 81 | 52 of 99 | 180 | NCT00126581 | Trial comparisons |
| Arm A: Erlotinib vs Arm B: Erlotinib/Carboplatin/Paclitaxel: serious adverse events | 21 of 81 | 39 of 99 | 180 | NCT00126581 | Trial comparisons |
Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST vs Aflibercept 4.0 mg/kg Arm Assessed by RECIST: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). | 0 of 84 | 0 of 84 | 168 | NCT00284141 | Trial comparisons |
| Erlotinib vs Pemetrexed: serious adverse events | 0 of 61 | 0 of 62 | 123 | NCT01565538 | Trial comparisons |
| Dacomitinib: Cohort A vs Dacomitinib: Cohort B: serious adverse events | 29 of 89 | 9 of 30 | 119 | NCT00818441 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 28 of 67 | 26 of 42 | 109 | NCT03909971 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 23 of 67 | 16 of 42 | 109 | NCT03909971 | Trial comparisons |
| 150 mg Nintedanib + Docetaxel vs 200 mg Nintedanib + Docetaxel: deaths from any cause | 0 of 7 | 0 of 7 | 14 | NCT02668393 | Trial comparisons |
| 150 mg Nintedanib + Docetaxel vs 200 mg Nintedanib + Docetaxel: serious adverse events | 3 of 7 | 2 of 7 | 14 | NCT02668393 | Trial comparisons |
| ALK-inhibitor Naive Patients vs Patients Recieved Prior ALK Inhibitor: Overall Survival | 8 of 8 | 5 of 5 | 13 | NCT02513667 | Trial comparisons |
| ALK-inhibitor Naive Patients vs Patients Recieved Prior ALK Inhibitor: Number of Participants With Adverse Events | 7 of 8 | 5 of 5 | 13 | NCT02513667 | Trial comparisons |
| ALK-inhibitor Naive Patients vs Patients Recieved Prior ALK Inhibitor: Number of Patients With CR/PR/Stable Disease for 12 Months | 2 of 8 | 2 of 5 | 13 | NCT02513667 | Trial comparisons |
| ALK-inhibitor Naive Patients vs Patients Recieved Prior ALK Inhibitor: deaths from any cause | 0 of 8 | 0 of 5 | 13 | NCT02513667 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005061/comparisons